Anticancer Therapies – Products

Sino Biological offers a wide range of recombinant CD2 and CD58 proteins and antibodies to support elucidating key interactions and pathways and shedding light on potential therapeutic strategies.

Plasma-based proteomic platform predicts clinical benefit from immune-checkpoint inhibitors in NSCLC, melanoma, and HPV-related cancers.

The Applied Biosystems™ Axiom™ BloodGenomiX™ Array and Software provide a high-throughput solution for more precise blood matching research.

This app note explores the use of an assay to facilitate rapid monitoring of T-cell function and simultaneous assessment of cell phenotype, activation markers, proliferation, viability and cytokine secretion.

On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.

Breakthrough medium delivers speed and scale to CAR-T cell therapy manufacturers.

The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma

In this compendium, Technology Networks presents a collection of handpicked resources, including infographics, listicles, an article and webinar, that will help you to learn more about the latest advancements with disease modeling and cancer immunotherapies.

N4 Pharma PLC (AIM: N4P), recently acquired a controlling interest in Nanogenics Limited.